- Home
- / Juno Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Juno Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$111.9 M
FY, 2017
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
| Revenue | 18.2M | 79.4M | 111.9M |
| Revenue growth, % | 335.7% | ||
| General and administrative expense | 51.1M | 70.7M | 108.1M |
| Operating expense total | 256.3M | 335.0M | 559.6M |
| EBIT | (244.1M) | (255.6M) | (447.8M) |
| EBIT margin, % | -1340.1% | -322.1% | -400.3% |
| Interest expense | 1.7M | 5.9M | 8.4M |
| Pre tax profit | (242.1M) | (256.2M) | (443.1M) |
| Income tax expense | (2.8M) | (10.7M) | (6.0M) |
| Net Income | (239.4M) | (245.6M) | (437.1M) |